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The biotechnology' age began in 1973 with the publication of a
research paper by Cohen and Boyer detailing their experiments in which
they created a functional bacterial plasmid in vitro.2 This initial report
explained how to splice two different DNA strands together and create an
entirely new and functional DNA molecule. This development, although
ground-breaking, immediately raised questions about the risks involved
with the application of this technology. In a letter to Science the following
year, several Nobel prize-winning scientists voiced their concerns over
recombinant DNA (hereinafter "rDNA") technology.3  The group,
including James Watson, proposed a moratorium on research using rDNA
technology until a general meeting of scientists could be held. This
proposed meeting was held in Asilomar, California in 1975. The output of
the Asilomar conference was a set of conclusions about the potential uses
of rDNA and recommendations for its regulation and safe use.5
The regulation of rDNA technology evolved from its beginnings in
Asilomar. The Asilomar conference's non-binding recommendations
were later used as the basis for the National Institutes of Health's
(hereinafter "NIH") rDNA mandatory safety requirements. 6  The NIH's
mandatory guidelines, however, applied only to research groups using
1 Biotechnology, broadly defined as "the application of scientific and engineering
principles to the processing of materials by biological agents to provide goods and
services," ALAN T. BULL ET AL., ORG. FOR ECON. CO-OPERATION & DEV.,
BIOTECHNOLOGY: INTERNATIONAL TRENDS AND PERSPECTIVES 18 (1982) (internal
quotation marks omitted), available at http://www.oecd.org/dataoecd/34/9/2097562.pdf,
has technically been around for centuries. The use of yeast to make beer and wine is
technically a use of biotechnology. The advent of recombinant DNA technology has
allowed scientists to manipulate organisms used in providing goods and services, leading
to what many have come to think of as modem-day biotechnology.
2 See Stanley N. Cohen et al., Construction ofBiologically Functional Bacterial Plasmids
In Vitro, 70 PROc. NAT'L ACAD. SCI. 3240 (1973).
3 See Paul Berg et al., Potential Biohazards ofRecombinant DNA Molecules, 185 SCI.
303 (1974).
5 See Paul Berg et al., Summary Statement of the Asilomar Conference on Recombinant
DNA Molecules, 72 PROC. NAT'L ACAD. SCI. 1981, 1981-83 (1975).
6 Recombinant DNA Research, 41 Fed. Reg. 27,902, 27,902 (July 7, 1976).
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federal funds.7 Any groups with independent means were free to take
these rules under advisement but were not required to comply. Then, in
1986, the United States federal government published its own regulations
in the Federal Register. These regulations, the Coordinated Framework
for Regulation of Biotechnology (hereinafter "Coordinated Framework"),
have remained the basis of biotechnology regulation.8 The Coordinated
Framework uses the joint efforts of three federal agencies, the Food and
Drug Administration (hereinafter "FDA"), the Environmental Protection
Agency (hereinafter "EPA"), and the United States Department of
Agriculture (hereinafter "USDA"), to regulate biotechnology.
Since the 1980s, the use of biotechnology has been both successful
and controversial. Early on, many developments were not controversial as
researchers were able to create plants that were resistant to a variety of
chemicals. 9  In 1987, five applications for field trials of genetically
modified (hereinafter "GM") plants were approved, and since that date,
more than 12,000 field trials have been approved by government
agencies. 0
More controversial, the 1980s also saw the creation of GM
microorganisms for biotechnology uses." Researchers in California
created a strain of Pseudomonas fluorescens that incorporated a gene,
which when expressed, produced an anti-freeze protein that delayed ice
crystal formation.12 This organism was named the "ice-minus" strain.'3
The creators of this organism were interested in its potential agricultural
applications for use in preventing frost damage to plants during the fall
growing season.14  To test its potential viability as a biotechnology
product, field tests were necessary. The creators applied for regulatory
' See id
8 See Coordinated Framework for Regulation of Biotechnology, 51 Fed. Reg. 23,302
(June 26, 1986).
9 Alan McHughen & Stuart Smyth, US Regulatory System for Genetically Modified
[Genetically Modified Organism (GMO), rDNA or Transgenic] Crop Cultivars, 6 PLANT
BIOTECHNOLOGY J. 2, 4 (2008).
'
0 Id. at 5.
"1 See Jean L. Marx, Assessing the Risks ofMicrobial Release, 237 ScI. 1413 (1987).
12 Id. at 1413-14.




approval of field tests; and after two years of delay, their applications were
approved.15  Unfortunately, public sentiment was not on their side.16
Opposition to the field trials was strong enough to further delay the
testing.' 7  Eventually, the field tests were moved to a new location,
approved, and completed, although the product eventually proved not to
be commercially viable.'8
Applications of biotechnology have evolved over the last thirty years.
In early 2009, the FDA approved the first pharmaceutical produced by
livestock; an anti-clotting factor produced in goat milk.19 This was the
first such approval of a pharmaceutical produced in a GM animal;
however, humans have long taken pharmaceuticals from animals, such as
insulin from pigs and cows. This regulatory approval shows the world
that pharmaceutical-producing GM animals are not inherently dangerous
and should reassure some critics of GM animals' safety. Also, hopefully
this will lead to the approval of more pharmaceutical-producing GM
animals.
In terms of molecular complexity, GM insects lie between
pharmaceutical-producing livestock and GM crops. The first of these
organisms, created before the rDNA revolution, set precedence for
effectiveness. In the 1950s and 1960s, to cope with costly screwworm
infestations, scientists used the Sterile Insect Technique (hereinafter
"SIT") 20 to drastically reduce the worm burden in the southern United
15 Marjorie Sun, Local Opposition Halts Biotechnology Test, 231 SCI. 667, 667 (1986).
16 id.
17 Id.
18 Gary E. Marchant, Modified Rules for Modified Bugs: Balancing Safety and Efficacy in
the Regulation ofDeliberate Release of Genetically Engineered Microorganisms, 1
HARv. J.L. & TECH. 163, 165 (1988).
19 Andrew Pollack, F.D.A. Approves Drug from Gene Altered Goats, N.Y. TIMES, Feb. 7,
2009, at B I, available at http://www.nytimes.com/2009/02/07/business/07goatdrug.html.
20 The Sterile Insect Technique, is still a GM technique, though it does not involve rDNA
technology. See R.C. Bushland et al., Eradication ofScrew- Worms Through Release of
Sterilized Males, 122 SCI. 287, 287 (1955).
SIT generally uses male insects, sterilized through exposure to radiation or a chemical,
released at the proper proportion into the wild to mate with wild type females who only
mate one time. Id.
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States.21 Since those early efforts to protect agricultural investments using
modified insects, many more experiments have been done with hopes of
eliminating vectors of disease and other agricultural pests, as well as
genetically "enhancing" some insect species.
In the United States, only two GM insects have been approved for a
field test. The first, a predatory mite, was released into a controlled
22
environment in 1996. These mites, though genetically modified,
contained only the lacZ gene. This gene was used solely for testing gene
migration from the GM mites to the native population. 23 The second test
insect, the pink bollworm, is a pest whose larvae cost cotton farmers
several million dollars a year.24 The GM bollworms contained a green
fluorescent protein gene which allowed investigators to more easily gauge
mating of GM insects with the natural population.25 The GM bollworms
were released in contained field trials in Phoenix in 2001, but the trials
were largely unsuccessful.26 Currently, although outside of the purview of
the United State's Coordinated Framework, Malaysia is considering the
release of a GM version of Aedes aegypti, an important disease vector.27
This release is the latest attempt to curb dengue fever transmission. 28
Although there have only been two approved applications for
controlled release of GM insects, many more may soon be applying for
regulatory approval. Between the advances in molecular techniques,
increased understanding of insect behavior and the ever-growing demand
to combat morbidity and mortality associated with vector-borne diseases,
21 G. DAVIDSON, GENETIC CONTROL OF INSECT PESTS 32-35 (1974).
22 MaiOrie A. Hoy, Transgenic Arthropods for Pest Management Programs: Risks and
Realities, 24 EXPERIMENTAL & APPLIED ACAROLOGY 463, 478 (2000).
23 id.
24 Aaron Bouchie, First GMInsect Field Trial Planned in US, NATURE BIOTECHNOLOGY,
April 2001, at 297.
25 Id.
26 PEW INITIATIVE ON FOOD & BIOTECHNOLOGY, BUGS IN THE SYSTEM? ISSUES IN THE
SCIENCE AND REGULATION OF GENETICALLY MODIFIED INSECTS 6 (2004), available at
http://www.pewtrusts.org/uploadedFiles/wwwpewtrustsorg/Reports/Food-andBiotechno
logy/pifb bugs 012204.pdf.
27 Susan Aldridge, Genetically Modified Mosquitoes, NATURE BIOTECHNOLOGY, July
2008, at 725.28 d
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research on GM insects is booming. In light of these promising advances
and the likely corresponding increase in GM insects seeking regulatory
approval, an examination of the Coordinated Framework and the path GM
insects' creators must travel for regulatory approval is needed.
This paper is divided into two major sections. The first is the
introductory section that investigates the motivations for the creation of
GM insects and the techniques used by scientists. The section also will
report on the successes and failures of GM insects, and the public's
response to these organisms. The second section will analyze the
regulatory framework. This section will first focus on the broader
Coordinated Framework and how it generally applies to biotechnology
and then on the regulatory path for GM insects.
I. THE SCIENCE OF AND PUBLIC RESPONSE To GM INSECTS
A. Motivations for GM Insects
There are several reasons why scientists wish to alter the genes of
insects. Important motivations like human health and agricultural
prosperity have driven this research. This section will first address
motivations associated with human health, focusing on vectors-borne
diseases. The second section will focus on agricultural motivations,
including pests of crops and livestock.
1. Human Health
The preservation of human health is a major driving force behind the
push for GM insects. Recent World Health Organization data indicates
that between seven diseases (malaria,2 9 dengue fever,30 lymphatic
29 World Health Organization, Malaria,
http://www.who.int/mediacentre/factsheets/fs094/en/print.html (last visited Nov. 11,
2009) (stating there were 247 million infections in 2006).
30 World Health Organization, Dengue and Dengue Hemorrhagic Fever,
http://www.who.int/mediacentre/factsheets/fs l7/en/print.html (last visited Nov. 11,
2009) (stating there were fifty million yearly infections).
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filariasis,3 1 yellow fever,32  leishmaniasis,33  Chagas' disease,34  and
African sleeping sickness 35) account for close to one-half billion
infections each year. The common thread among these seven infectious
diseases is that each is transmitted by insects. Although there is growing
attention paid to these diseases through efforts such as the Gates'
Foundation's partnership with the World Health Organization in the "Roll
Back Malaria" effort, 36 funding for combating many of these diseases is
still drastically inadequate. Amazingly, only one percent of the fourteen
hundred drugs approved between 1975 and 1999 were for tropical
diseases.37
Even when chemotherapies are developed for these diseases, troubles
still arise. There are a variety of issues that can arise; most important to
Western pharmaceutical companies is that these diseases largely occur in
the developing world. With the costs of gaining regulatory approval for a
drug or biologic nearing one billion dollars, there would be little
opportunity for these companies to profit on investment if the new drug is
aimed toward low income nations. Another potential problem with the
31 World Health Organization, Lymphatic Filariasis,
http://www.who.int/mediacentre/factsheets/fsl02/en/print.html (last visited Nov. 11,
2009) (stating there were approximately 120 million infections affected by this disease).
32 World Health Organization, Yellow Fever,
http://www.who.int/mediacentre/factsheets/fsl00/en/print.html (last visited Nov. 11,
2009) (stating there are 200,000 yellow fever infections each year).
3 World Health Organization, Magnitude of the Problem,
http://www.who.int/leishmaniasis/burden/magnitude/burden-magnitude/en/print.html
(last visited Nov. 11, 2009) (stating approximately two million new cases are seen each
Sear).4 Centers for Disease Control and Prevention, Chagas Disease - Detailed Fact Sheet,
http://www.cdc.gov/print.do?url=http%3A//www.cdc.gov/chagas/factsheets/detailed.html
(last visited Nov. 11, 2009) (stating that there are between eight and eleven million
infections of Chagas' disease).
3 World Health Organization, African Trypanosomiasis (Sleeping Sickness),
http://www.who.int/mediacentre/factsheets/fs259/en/print.html (last visited Nov. 11,
2009) (stating there are between fifty and seventy thousand infections each year).
36 See generally Roll Back Malaria (RBM) Partnership, http://www.rollbackmalaria.org/
(last visited Nov. 11, 2009).
3 World Health Organization, 10 Facts on Neglected Tropical Diseases,
http://www.who.int/features/factfiles/neglected-tropicaldiseases/en/index.html (last
visited Nov. 11, 2009).
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deployment of a treatment or vaccination regimen is the break down in the
"cold chain." The "cold chain" is the supply chain in which a product
requiring refrigeration is maintained at a low temperature during transit to
ensure potency and prevent spoilage. 38 The problem here arises, once
again, because of the populations for which these products are intended.
These are some of the poorest communities in the world. Often times,
treatment sites may not have electricity to maintain the cold chain, leading
to likely spoilage of any pharmaceuticals that make it to that locale.
Another problem that arises in the development of chemotherapeutics
is drug resistance. Even when pharmaceutical companies work to produce
chemotherapeutic agents, the targeted organisms are quickly adapting. An
organism illustrative of this disturbing phenomenon is Plasmodium
falciparum, the etiological agent of malaria, which is one of the most
devastating vector-borne diseases. Traditionally, this parasite was
controlled with quinine; 39 a drug initially derived from the bark of the
chinchona tree several centuries ago. In the early 20th Century, a more
40
effective derivative agent was created: chloroquine. Thereafter,
resistance to anti-malarial compounds soon began to surface in Southeast
Asia.41 Other agents were developed, and in the case of each drug,
resistance began to appear.42 Significantly, resistance was recently
discovered for the latest "miracle drug," a traditional Chinese anti-
malarial, artemisinin. 43 Malaria is not the only vector-borne disease to
develop dru resistance; similar phenomena have been seen in
leishmaniasis and sleeping sickness, 45 among other tropic diseases.
3 See DEP'T OF VACCINES & BIOLOGICALS, WORLD HEALTH ORG., ADOPTING GLOBAL
VACCINE MANAGEMENT POLICIES FOR NATIONAL USE annex A, at 29 (2002), available at
http://www.who.int/vaccines-documents/DocsPDFO2/www713.pdf.
39 Karen Hayton & Xin-zhuan Su, Drug Resistance and Genetic Mapping in Plasmodium
falciparum, 54 CURRENT GENETICS 223, 226 (2008).
4 Id. at 224.
41 id
42 See id.
43 See Harald Noedl et al., Evidence ofArtemisinin-Resistant Malaria in Western
Cambodia, 359 NEw ENG. J. MED. 2619 (2008).
" See Simon L. Croft et al., Drug Resistance in Leishmaniasis, 19 CLINICAL
MICROBIOLOGY REV. 111 (2006).
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These organisms' ability to rapidly reproduce, together with strong drug
pressures on the microorganism population, will continue to lead to the
spread of drug resistance.
Additionally, hardships have also been seen when nations attempt to
combat the disease vectors. The major method of combating disease
vectors is through the use of insecticides. Two modes of delivery are
generally preferred: direct spraying on vector habitats or through the use
of insecticide-impregnated bed nets. The more widely used method, direct
spraying on vector habitats, leads to two major problems: environmental
or human effects and insecticide resistance.
The impact on humans is a major concern with the spraying of
insecticides. One report gathered data from smaller cohort studies and
concluded that exposure to certain chemicals, including dichlorodiphenyl
tricholorethane (hereinafter "DDT"), correlates with delays in cognitive
and neuromuscular development in children.46 Another study concluded
that DDT can have a serious impact on a child's endocrine system. 47 In
addition to DDT, other pesticides have been severely limited from once-
broad applications because of concerns over potential impacts to human
health.
Environmental concerns also arise from the spraying of insecticides.
In Egypt, the spraying of insecticides has led to major problems with farm
animal poisonings, death of beneficial insects, as well as pollution of the
food and water supply. 49 Additionally, the EPA published a report stating
45 See Pascal Maser et al., Drug Transport and Drug Resistance in African
Trypanosomes, 6 DRUG RESISTANCE UPDATES 281 (2006).
46 Susan A. Korrick & Sharon K. Sagiv, Polychlorinated Biphenyls, Organochlorine
Pesticides and Neurodevelopment, 20 CURRENT OPINION PEDIATRICS 198, 202-03
(2008).
47 See Walter J. Rogan & N. Beth Ragan, Some Evidence ofEffects ofEnvironmental
Chemicals on the Endocrine System in Children, 210 INT'L J. OF HYGIENE & ENVTL.
HEALTH 659 (2007).
48 See L. RITTER ET AL., INT'L PROGRAMME ON CHEM. SAFETY, A REVIEW OF SELECTED
PERSISTENT ORGANIC POLLUTANTS (1995), available at
http://www.who.int/ipcs/assessment/en/pcs_9539_2004_05_13.pdf.
49 Sameeh A. Mansour, Environmental Impact ofPesticides in Egypt, 196 REV. ENvTL.
CONTAMINATION & TOXICOLOGY 1 (2008).
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that a major concern associated with DDT was its environmental impact.o
To help ensure that both human health and environmental concerns are
minimized, the World Health Organization has created the WHO
Pesticides Evaluation Scheme.5 ' This program evaluates and makes
recommendations concerning the regulations of these potentially deadly
chemicals. 52
In addition to human and environmental concerns, incidents of
insecticide resistance have been observed. According to one review of the
scientific literature, more than 500 insect species have acquired some type
of resistance to insecticides. 53 These resistances often develop to more
than one class of insecticide, making control efforts more difficult. 54 To
attempt to monitor and keep abreast of resistance developing in the field,
the World Health Organization publishes a manual with insecticide-
resistance detection techniques.
Public health concerns are a major motivation for the development of
GM insects. There are serious issues involved in the development and
implementation of chemotherapeutics to treat infectious diseases
transmitted by insects. Additionally, direct attacks on insects can prove
costly to human health and the environment, and lead to the development
of insecticide resistance. Thus, major human health concerns are a driving
force in the push for GM insects.
5o U.S. ENvTL. PROT. AGENCY, DDT: A REVIEW OF SCIENTIFIC AND ECONOMIC ASPECTS
OF THE DECISION TO BAN ITS USE AS A PESTICIDE (1975), available at
http://www.epa.gov/history/topics/ddt/DDT.pdf.
51 See World Health Organization, WHO Pesticides Evaluation Scheme: "WHOPES,"
http://www.who.int/whopes/en/ (last visited Nov. 20, 2009).
52 id
s3 Marjorie A. Hoy, Myths, Models, and Mitigation ofResistance to Pesticides, 353 PHIL.
TRANSACTIONS ROYAL SoC'Y LONDON 1787, 1787 (1998).
54 See id.
5 See JANET HEMINGWAY & WILLIAM BROGDON, DEPARTMENT OF DISEASE PREVENTION
AND CONTROL, WORLD HEALTH ORG., TECHNIQUES TO DETECT INSECTICIDE RESISTANCE
MECHANISMS (1998), available at
http://whqlibdoc.who.int/hq/1998/WHOCDSCPCMAL_98.6.pdf.
72
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2. Agricultural Concerns
Agricultural concerns were the original motivation for modifying
insects to alter the native population. The original use of GM insects was
implemented to deal with the burden of the New World screwworm. 56
The screwworm was a major agricultural pest in the southern United
States. The screwworm, a parasitic fly that lays its eggs in farm
animals' skin, was a 120 million dollar per year problem (1958 US
dollars). The development and emergence of larvae from the animals'
skin leads to problems such as carcass damage and secondary infections. 59
Additionally, a heavy larvae burden could kill younger animals.60  To
combat the economic problem associated with screwworm infestations,
"altered" insects were used. 6 1 Although not GM, these insects were the
beginnings of the GM insect movement.
In addition to alleviating concerns regarding farm animals, other
agricultural motivations, such as crop and plant pests, have pushed the
development of GM insects. One of the most important plant and crop
pests, in terms of economic impact, is the Mediterranean fruit fly. Not
only does this insect attack more than 250 different types of fruits, nuts,
and vegetables; it also leads to a constraint on trade. 62  These trade
restrictions stem from an importing country's fear that the fruit fly may be
harbored in imported agricultural products. Once released, the fruit fly
will operate as an invasive species, wreaking havoc on local flora. 63 This
huge economic concern is a strong motivator for development of GM
insects that can control this pest.
The Mediterranean fruit fly is not the only crop and plant pest that has




61 See Bushland et al., supra note 20.62 Peng Gong et al., A Dominant Lethal Genetic System for Autocidal Control of the




strengthened the call for GM insects. Additionally, pests of corn,6
65 66678cotton, cowpea, potatoes,67 and others are all important agricultural
pests with strong economic impacts that will further the call for GM
insects.
In addition to pests, there are other agricultural concerns that could
motivate the creation of GM insects. One major example is the honeybee.
Although not an agricultural 6Vest, the honeybee and its recent
disappearance is a major concern. Currently, the underlying mechanism
or pathogen associated with the honeybees' disappearance is unknown. 70
Further research could identify areas for potential genetic modification
that could alleviate this significant problem.
Finally, there is also a potential social impact of agricultural pests.
The destruction of agricultural outputs by pests leads to increased
consumer costs. Agricultural pests can lead to costs in the hundreds of
millions of dollars to the farmer, which will be passed on to the consumer.
Although in Western countries this increased cost could be absorbed by
the consumer, in developing countries this increase could put some foods
out of reach for import and purchase. These social costs, stemming from
the economic toll of pests, could be just as important as the economic
ones.
Overall, the huge economic and social impact of agricultural pests is a
strong motivator for the development of GM insects.
6 See generally J.D. DeVault et al., Gene Transfer into Corn Earworm, 6 GENOME
RESEARCH 571 (1996).
65 See generally J.J. Peloquin et al., Genetic Transformation of the Pink Bollworm,
Pectinophora gossypiella with the piggybac Element, 9 INSECT MOLECULAR BIOLOGY
323 (2000).
66 See generally Andre M. Murad et al., Proteomic Analysis ofMetarhizium anisopliae
Secretion in the Presence of the Insect Pest Callosobruchus maculatus, 154
MICROBIOLOGY 3766 (2008).
67 See generally N.T Mbungu & G. Boiteau, Flight Take-Off Performance of Colorado
Potato Beetle in Relation to Potato Phylogeny, 101 J. ECON. ENTOMOLOGY 56 (2008).
68 See generally Peter W. Atkinson, Genetic Engineering in Insects ofAgricultural
Importance, 32 INSECT BIOCHEMISTRY & MOLECULAR BIOLOGY 1237 (2002).69 Benjamin P. Oldroyd, What's Killing American Honey Bees?, 6 PUB. LIBR. SCI. &
BIOLOGY 1195, 1195 (2007).70 id
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3. Other Potential Motivators for the Development of GM Insects
In addition to public health and agricultural concerns, other
miscellaneous motivators exist for the development of GM insects. One
paradigm for this group is the silk worm, Bombyx mori. Silk worms are
quickly reproducing organisms that have the capability to produce massive
amounts of protein, most commonly silk.7 ' Recent developments in
scientific techniques have allowed researchers to create GM silk worms,
harnessing the strong protein production of the worm for production of
other proteins. One group recently created a GM strain of silkworms that
produce human antibodies. 72 This application could be expanded into
other innovations. Silkworms could be used as bioreactors, similar to
plants in the "Pharming" movement. This application, plus many other
potential uses, serves as further motivation for the creation of GM insects.
In conclusion, there are several motivating factors for the creation of
GM insects. These factors range from improving public health to
alleviating agricultural burdens due to insect infestations. Additionally,
insects can be genetically modified to produce beneficial products, similar
to procedures used in the Pharming movement. Overall, there is a strong
need for the development of these insects.
B. How to Make a GMInsect
There are several methods available to create GM insects, and two
broad categories of modifications. First, the modification can be directed
at the genome of the insect. This is the method usually associated with
GM insects. This method involves altering the insect's genome to result
in a chosen outcome, be it pathogen-resistance, sterility, or some other
desired trait. The second category, paratransgenesis, involves
modification of the gut flora of the insect. For instance, using this
technique, scientists are able to modify the insect's commensal organisms
71 Marian R. Goldsmith et al., The Genetics and Genomics ofthe Silkworm, Bombyx
mori, 50 ANN. REv. ENTOMOLOGY 71, 72 (2005).
72 See Enoch Y. Park et al., Human IgG1 Expression in Silkworm Larval Hemolymph




to interrupt the disease transmission cycle. This section will provide an
overview of these two processes.
1. Direct Genome Modification
Under the heading of direct genome modification, two subcategories
exist. The first is sterile insect technique (hereinafter "SIT"). The second
is genetic manipulation using rDNA technology. This section will
highlight both of these techniques
a. SIT
SIT, the oldest form of human-mediated direct genome modification,
has been largely successful.73 Pioneered by Knipling, SIT uses an insect
species against itself.74 Non-viable offspring is the goal of SIT; the sterile
males inseminate the females, producing non-viable eggs, thus reducing
the population. 7 The technique uses factory-bred, mass-reared male
insects that have been exposed to massive amounts of radiation or a
chemical mutagen.76  This exposure to radiation or other mutagens
damages the males' gametes. Gamete damage does not later prevent
insemination of wild females; however, it does lead to non-viable off-
spring.78
The next steps involve release. Prior to release of these sterilized
males, a population study must be performed. 79 These males must be
released in numbers approximately ten to 100 times more than the natural
population of males.8 The release of these excess sterile males aids in
competing with the wild type males.8 t Finally, once the proper numbers
7 See generally DAVIDSON, supra note 21, ch. 2.
74 See Bushland, supra note 20, at 287.




79 See id. at 17.
so See id. at 23, 28-29.
" Id. at 17.
76
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are determined, the males are released and monitored to determine the
success of the effort.
In spite of SIT's success, there are drawbacks to this technique. The
major drawbacks are the irradiation procedure and the limitations naturally
inherent in the technique. First, the irradiation process, in addition to
sterilizing the males, reduces the fitness of the males relative to the wild
population. 8 2 The weaker sterile males are at a disadvantage in the wild
and may not be selected by a female for mating. 8 3 The excess of released
males partially compensates for this weakness, but does not completely
alleviate it. The second drawback is the naturally inherent limitations in
the process. This 8Frocess can only work for insects that can be mass-
reared at facilities. Also, prior to implementation, much must be known
about the insects, including population dynamics and ecology. Finally, the
insects at the facility are in-bred, making the altered insects less fit than
their natural relatives, further making implementation difficult. In spite of
these complications, SIT has been successful.
b. Genetic Manipulation
Many of the recent advances in the field of genetically modifying
insects have come due to the rDNA revolution. This section is an
overview of this process.
Prior to the advent of the rDNA age, genetic manipulation was
possible, but limited to only the natural variations present in a species.
Modem techniques have expanded the realm of possible genetic
alterations.8 5 The initial step in genetic modification is the identification
of a desirable trait researchers wish to "drive" into a population.8 ' This
trait, ideally expressed from one gene, could lead to pathogen resistance or
82 See Alan S. Robinson & Gerald Franz, The Application of Transgenic Insect
Technology in the Sterile Insect Technique, in INSECT TRANSGENESIS 315 (2000).
" See id.
8 See DAVIDSON, supra note 21, at 6.
8s See Paul Eggleston & Yuguang Zhao, Targeted Transformation of the Insect Genome,
in INSECT TRANSGENESIS, supra note 82, at 29.86 The implications of selecting what traits to remove from a population, or conversely
"drive" in to a population, are a difficult decision, with serious potential consequences.
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it could be a lethal mutation, which, when activated, kills the organism.
Ideally, the trait selected would be from a related organism. This makes
integration and expression of the gene in the GM insect easier. 8  The
sequencing of several vectors' genomes aids in the selection of genes for
genetic modification.
After selection of a trait, researchers have two options for inserting the
gene into the insect's genome. The first option, transposons or "jumping
genes," have the ability to cut and paste themselves into and out of DNA.
Researchers can put the desired gene within a transposons' molecular
machinery and expose it to insect cells. 89 One of the drawbacks to this
technique is that the area into which the transposon integrates is relatively
random. There are certain sequences in DNA into which a transposon will
preferentially insert itself, but other than that, insertion is random. The
second option is through the use of viral vectors.90 Similar to transposons,
a desired gene can be spliced into a virus construct. Then, viral vectors
can be used to integrate into the genome, also on a random basis.91
After attempting to integrate the gene into the insect's genome,
researchers must ensure that the gene has been properly integrated and
expressed. This can be done by including a selectable marker within the
gene's vector or through checking for actual expression of the gene. 92
Although this technique appears straightforward, there are still
concerns with its application. The issues regarding spread of the gene to
non-intended population is a serious one, and will be discussed later.
There are other concerns, including, similar to SIT, the fitness of the GM
insects. GM insects, after receiving the new gene, are much less fit than
the wild type, making mating selection difficult. 93 After integration using
a transposon, it is possible that the gene will excise itself, and relocate to
another, non-expressing part of the genome. 94 In spite of these concerns,
87 PEW INITIATIVE ON FOOD & BIOTECHNOLOGY, supra note 26, at 15, 26.
88 See id. at 9.
89 Eggleston & Zhao, supra note 85, at 29-30.
90 1d.
91 PEW INITIATIVE ON FOOD & BIOTECHNOLOGY, supra note 26, at 10.
92 Eggleston & Zhao, supra note 85, at 31-33.
93 PEW INITIATIVE ON FOOD & BIOTECHNOLOGY, supra note 26, at 10.
94 id
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this type of genetic modification has promise for the future.
2. Paratransgenesis
In addition to direct genome modification, another tool available to
alter insects is paratransgenesis.95 This technique involves altering the
flora (or adding completely new flora) in the gut of an insect, but not
altering the insect's own genome. 96 Nearly all vectors transmit disease as
an unintended consequence of a hemataphagous lifestyle. Researchers can
use the interaction between the pathogen and the natural flora of the
insect's gut to destroy the disease agent.
One real life example of paratransgenesis in use is the kissing bug.
The kissing bug (Rhodnius prolixus) transmits Chagas' disease
(Trypanosoma cruzi). Researchers have been able to alter the bacteria
commonly found in the gut of the kissing bug to produce an anti-
trypanosome peptide, cecropin. 99 When expressed, this peptide does not
harm the insect, but is deadly to the pathogen. 100
This technique has a major advantage over direct insect genetic
modification; it does not involve modifying the insect's genome. Bacteria
are much easier to add or remove DNA because bacteria lack a nucleus.
Also, bacterial genetic techniques have been in use since 1973 and have
been extensively refined, relative to insect genetics techniques. 0 ' The
major drawback associated with paratransgenesis is its real world
application. Driving this modified bacterial strain into an insect
population in a sustainable manner will prove daunting.' 02
Overall, this section provided a cursory overview of techniques
scientists have developed to modify insects. These techniques range from
95 See generally Charles B. Beard et al., Bacterial Symbiont Transformation in Chagas
Disease Vectors, in INSECT TRANSGENESIS, supra note 82, at 289-98.
9 Id. at 289.
9 See id.
9 Id. at 289-90.
9 Id. at 293.
'" See id. at 294.
1'0 See Cohen et al., supra note 2.
102 Beard et al., supra note 95, at 298-300.
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directly modifying an insect's germ line, to destroying an insect's germ
line, to altering the natural flora of an insect. Although some of these
techniques have proven successful, much more work is needed before any
are perfected.
C. The Possible Drawbacks to GMInsects
Although there are strong motivations for the creation of GM insects,
there are still scientifically-valid concerns; many stemming from a lack of
data on this topic. This section will analyze the possible direct human
health and environmental impacts of GM insects. Please note that this
section will only address drawbacks considered to be scientifically-valid.
More common "mass-hysteria" concerns will be addressed below in "The
Public's Views" section.
1. Direct Impacts on Human Health
Although impacts on human health are possible through the alteration
of ecosystems due to GM insects, this section will cover potential direct
impacts. Direct consumption of insects, while not usually practiced in the
United States, could still be a problem globally. 103 As has been the case
with GM crops, there are concerns that additionally expressed proteins in
GM insects could lead to an allergic reaction.1 04 To address this issue,
allergenicity testing of these expressed proteins should be performed.
An additional concern is the consumption of insect products. For
instance, humans consume honey. If a honeybee was genetically
engineered to resist the plague that is currently decimating this population,
allergenicity testing must be performed to ensure that the honey produced
by such altered bees is a relatively safe product. 05
The final concern is the potential alteration of the insect itself.
Although purely hypothetical, GM insects, no longer able to transmit
disease X, could now be competent to transmit disease Y. Also, the trait
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conferred on a GM insect could make it more fit and potentially expand its
geographic reach, meaning more people could be exposed to the insect.
Overall, these concerns are serious, but are largely unsubstantiated.
Little data exists and many of these concerns stem from a fear of the
unknown.
2. Environmental Impacts
Environmental concerns are pervasive in the GM field. These issues
vary by choice of GM technique. The concerns associated with the SIT
differ from those stemming from direct genome modification.
The environmental concerns surrounding the use of the SIT to
eliminate or control a native population stem from a permanent alteration
of the ecosystem. If the SIT is a success, and a population is either
eliminated or vastly reduced, the ecosystem is permanently altered. o0 It is
difficult to predict all of the broader ecological impacts of these changes.
It is possible that the elimination or vast reduction in numbers of this
organism could have dire consequences for other non-targeted
organisms.107 A likely food source and predator will have been eliminated
and this could have a serious impact. Scientists have emphasized that pre-
release investigation of the targeted organism's ecology must be
performed to plan for these environmental impacts. 0 8
Concerns with direct insect genome modification differ from those
associated with the SIT. The goals of these two techniques differ; SIT's
goal is population elimination or control, whereas direct genome
modification's goal is population replacement, so there is unlikely to be
the same impact on the population of the target species. The idea of
horizontal gene flow is a concern with direct genome modification.' 0 9
Critics of GM insects fear that genes inserted into an insect's genome via
10
' See id. at 3 1.
107 See id.
1os See Thomas W. Scott et al., The Ecology of Genetically Modified Mosquitoes, 298
SCI. 117, 119 (2002).
'
09 PEW INITIATIVE ON FOOD & BIOTECHNOLOGY, supra note 26, at 36. Horizontal gene




transposons will have the ability to "jump" from the GM insect to other
organisms. 110 These fears are at least partially grounded in real science.
The machinery used to originally insert genes into the insect's genome is
mobile by nature, and thus scientists are concerned that the genes will
continue to "jump" once the GM insect is released into the
environment.111 Depending on what the gene is, this could impact other
species' fitness in their natural environment. No data, however, supports
this concern. 112
In conclusion, these concerns are valid (for now) because of the
current lack of scientific literature and actual experience. Once more
research is conducted, these concerns will either be confirmed or
dispelled.
D. The Public's Views
Similar to all GM organisms, there is a broad spectrum of public
approval and disapproval of GM insects. Ideas range from positive, pro-
GM insect views to the commonly found anti-GM sentiments. This
section reports on the two different societal views of GM insects.
1. Pro GM Insects
Much of the public's concern revolves around which end of the risk
spectrum they find themselves. If one believes that the risk is minor and
the benefits will out-weigh the risks, there is generally a positive
sentiment; this is the pro-GM insect group. This group focuses on the
beneficial financial (including agricultural) and human health impacts GM
insects can provide." 3
"
0 See id. at 34-37.
.. See Ronald H.A. Plasterk, Molecular Mechanisms of Transposition and Its Control,
74 CELL 781, 781 (1993).
"
2 PEW INITIATIVE ON FOOD & BIOTECHNOLOGY, supra note 26, at 38.
" See, e.g., Stephen Evans, Worm Turns for US Cotton Farmers, BBC NEWS, WORLD
EDITION, June 20, 2002, http://news.bbc.co.uk/2/hi/science/nature/2053884.stm; Arlene
Weintraub, Much Ado Over "Lethal Genes, " Bus. WEEK, Jan. 16, 2006,
http://www.businessweek.com/magazine/content/06_03/b3967112.htm; Scientists Say
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Currently, there is not much discussion regarding GM insects in public
fora. Scientists have previously discussed GM insects and have generally
advocated GM insects as an "eco-friendly" way of eliminating insect
pests.114 Outside of the implementation of the SIT for screwworms and
other organisms, no GM insects have been released in a non-field trial
setting. Thus, there has yet to be a true "lightning rod" incident to test the
public sentiment." 5  Perhaps with the release of GM mosquitoes in
Malaysia and a corresponding success of reducing dengue fever, more
public sentiment will swing in favor of GM insects.l
2. Anti-GM Insects
All technologies have critics. One of the major driving forces behind
criticism of GM insects is the main rationale for releasing GM insects: free
release. A concern associated with biotechnological products is the lack
of control over those organisms. With GM insects, especially those with
direct genome modifications, the goal is free release and population
replacement. As discussed in section C, potential problems could arise;
however, there is limited data available to support any valid conclusions
that GM insects will destroy ecosystems." 7
The "anti-GM insects" position is based largely on fears of horizontal
gene transfer, ecosystem collapse, and lack of regulation."' 8 These fears
highlight the one true problem associated with GM insects: a lack of
knowledge. The idea of an insect with a foreign gene inserted into its
genome can be frightening; however, when the population is apprised of
Genetically Modified Insects Can Improve Health and Farming,
http://www.gmofoodforthought.com/2005/1 1/scientists say geneticallymod.htm (Nov.
12, 2005, 17:01 EST).
114 See, e.g., Ernst A. Wimmer, Eco-Friendly Insect Management, 23 NATURE
BIOTECHNOLOGY 432 (2005).
115 There have been small, very controlled releases of genome modified insects in
California and Florida, but no completely wild release has been achieved yet. See PEW
INITIATIVE ON FOOD & BIOTECHNOLOGY, supra note 26, at 18; Hoy, supra note 22, at
475.
116 See Aldridge, supra note 27.
'
17 PEW INITIATIVE ON FOOD & BIOTECHNOLOGY, supra note 26, at 38.
118 See id. at 34-37, 50.
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that gene's function(s) and the benefits associated with it, the public's
opinions may change.
The lack of knowledge issue is highlighted by anti-GM insect
propaganda spread by activist groups. The anti-GM insect side uses this
lack of knowledge to scare the public. They use words like
"frankenbugs,"ll9 "ecological dynamite,"l20 and phrases like "ill-
conceived arrogance of industry scientists who are playing havoc with my
world"'21 to describe the GM insect initiative. Also, the anti-GM
movement attempts to raise concerns about how transposons could make
the move from GM insects to humans and other organisms.122 It is never
mentioned, however, that these DNA elements are ubiquitous throughout
nature, and that horizontal gene transfer outside of the laboratory rarely
occurs.123
This propaganda can change people's unbiased perceptions of the
technology and lead to scary consequences. This phenomenon was seen in
India when a newspaper article was able to destroy valuable research. In
1975, two days before the implementation of an SIT program to reduce the
mosquito population in India, a newspaper reported that the program was
actually a test of the United States' biological weapons.124 This article led
to mass hysteria among residents and the Indian government ending this
potentially life-saving exercise. 125  This illustrates how misinformation
can have a profound impact on social progress.
In conclusion, GM insects have not yet polarized the global population
in the same way as GM crops. After more public tests and the possible
commercial release of GM insects, however, these pro and anti-GM
"
9 Jeffrey Benner, Frankenbugs in the Wings, ORGANIC CONSUMERS Ass'N, Dec. 7,
2001, http://www.organicconsumers.org/clothes/geinsects.cfm.
120 Rick Weiss, Mutant Bugs: Genetically Altered Heroes or Spineless Menaces?, WASH.
POST, Dec. 18, 1996, at A03 (quoting Jeremy Rifkin).
121 Rima E. Laibow, Med. Dir., Natural Solutions Found., GM Files: Genetically
Modified Insects (Oct. 23, 2008), http://www.healthfreedomusa.org/?p-1252.122 Joe Cummins, Professor Emeritus of Genetics, Univ. of W. Ontario, Transgenic Pink
Bollworms FONSI? (Dec. 14, 2001), http://www.i-sis.org.uk/pinkbollworms.php.
123 Margaret G. Kidwell & Damon Lisch, Transposable Elements as Sources of Variation
in Animals and Plants, 95 PROC. NAT'L ACAD. SCI. 7704, 7704-05 (1997).
124 PEW INTIATIVE ON FOOD & BIOTECHNOLOGY, supra note 26, at 46.
125 See id.
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positions are likely to grow to be more entrenched and more vocal.
E. The Potential Impacts - Surrogate Models
There has yet to be a public, non-confined release of GM insects (not
including SIT insects). Thus, there is yet to be a situation where GM
insects have "over-stepped" their bounds and made an impact where one
was not needed or wanted. This section will describe two occasions where
non-GM insects were released and a negative impact resulted on the native
populations. These occurrences can serve as a model for potential
unintended consequences of the release of GM insects. The first case is
the cactus moth and the second is the "Africanized" honeybee.
1. The Cactus moth
The cactus moth has been used as a biological control mechanism
since the 1920s.126 It is a pest of several species of Opuntia cactus and is
imported with the goal of destroying these invasive cacti. 127 The cactus
moth has been successful in destroying this invasive cactus species where
it has been released, including its 1957 release in the Caribbean. 128 In the
early 21st century, however, the cactus moth was discovered in Florida.129
The moth has never been deliberately released in the continental United
States.130 More importantly, it was also discovered that the moth was
attacking an endangered native species of cactus. 13 1 This invasion of
Florida is still being combated in an effort to save the endangered cacti.132
The cactus moth serves as a lesson to those who wish to use GM
insects to control agricultural pests and disease vectors, but have not
looked at the invasiveness of the insect and the potential unintended
126 H. G. Zimmermann et al., The Renowned Cactus Moth, Cactoblastis cactorum: Its
Natural History and Threat to Native Opuntia Floras in Mexico and the United States, 84
FLA. ENTOMOLOGIST 543, 543 (2001).
127 jd
128 Id. at 543-44.





consequences. GM insects will not usually involve release of a new
species into an ecosystem that previously lacked that species, which was
the case with the cactus moth. These factors are difficult to determine
ahead of time; close and careful monitoring will be needed when GM
insects are released.
2. "Africanized" Honeybees
African honeybees were originally introduced to the Western
Hemisphere in South America in 1956 to produce a population of bees
which could adequately produce honey in tropical climates.' 33 Initially, it
was thought that the African and European (native species found in North
and South America) bees would mate and produce a hybrid population,
making the European population of bees "Africanized." Unfortunately,
these African bees were accidentally released from their confined
environment.' 3 5 The population of African bees began migrating north
and in 1990 reached the United States.136 In the last twenty years, the
bees have colonized southern regions of Texas, New Mexico, Arizona,
and California.137 Interestingly, in those states, the European honeybee
species have not been displaced, but rather the two populations have
hybridized, forming a new, more aggressive subspecies. 1 Efforts to
control this new species have been unsuccessful.139
"Africanized" honeybees serve as an example of how quickly a
population can spread throughout a region with negative consequences.
Also, the entire African honeybee population explosion began as the result
of a simple accident. An individual left a bee crate open, thus allowing for
a few to escape.140 This serves as a warning for testing GM insects: once
" Stanley Scott Schneider et al., The African Honey Bee: Factors Contributing to a
Successful Biological Invasion, 49 ANN. REv. ENTOMOLOGY 351, 351 (2004).
134 M. Alice Pinto et al., Africanization in the United States: Replacement ofFeral
European Honeybees by an African Hybrid Swarm, 170 GENETICS 1653, 1653 (2005).
35Id
I36 d.
137 Id at 1654.
138Id
1 See id at 1653.
140 See id
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these organisms are released, the organism can likely never be brought
back under control.
II. REGULATION OF GM INSECTS
The current regulatory framework for GM products is a convoluted,
largely unorganized patchwork of administrative regulations and statutes.
This section will analyze the current regulatory framework and how it
might apply to GM insects. It will begin with an introduction to the
Coordinated Framework. Next, it will discuss the statutes and
administrative agencies likely involved in regulating GM insects. A final
section will briefly cover an international regulatory scheme.
A. Coordinated Framework
In the ten years after Cohen and Boyer's report, GM techniques
rapidly advanced and were transitioning from the lab bench to the real life
applications. These developments, in addition to the confusion associated
with the regulation of biotechnology, prompted the Reagan administration
to assemble an interagency working group under the White House Council
on Natural Resources and the Environment in the Office of Science and
Technology Policy (hereinafter "OSTP").141 This group, the Working
Group on Biotechnology, initially offered a notice seeking public
comment in the Federal Register on the following: (1) U.S. laws related to
biotechnology; (2) policies of major regulatory agencies; and (3) how
federal agencies should coordinate regulation.142 After a comment period,
the OSTP announced its official policy in the Coordinated Framework in
June 1986.143
The policy announced in the Coordinated Framework was based on
three conclusions. The Working Group was operating under a goal of
trying to protect human health and the environment while maintaining
141 Proposal for a Coordinated Framework of Regulation for Biotechnology, 49 Fed. Reg.
50,856, 50,856-57 (Dec. 31, 1984).
142Id. at 50,856.
143 Coordinated Framework for Regulation of Biotechnology, 51 Fed. Reg. 23,302,
23,302 (June 26, 1986).
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relative regulatory certainty to provide incentives for growth of the
biotechnology industry.144 This led to the first conclusion that, for the
most part, current laws provide an adequate framework from which
biotechnology can be regulated.145 Second, products of the biotechnology
process would be regulated, rather than the process itself.146 The final
conclusion was that relative to non-biotechnology goods, biotechnology
products pose no unique risks.14 7  Based on those conclusions, the
Coordinated Framework established a broad regulatory network.
The regulatory network adopted in the Coordinated Framework is a
patchwork grouping of federal agencies. The Coordinated Framework
includes six federal agencies: FDA, EPA, USDA, NIH, the National
Science Foundation (hereinafter "NSF"), and the Occupational Safety and
Health Administration (hereinafter "OSHA"). 148 Although the NIH,149
NSF, and OSHA are vital for biotechnology regulation, the major agencies
for implementation of the Coordinated Framework are the FDA, EPA, and
USDA.' The Coordinated Framework concluded that the major statutes
associated with each of these three agencies had the ability to cover
biotechnology and any changes necessary could be accomplished through
the promulgation of administrative regulations.' 5 '
The statutes and regulations associated with each of the agencies and
how each can be applied to the regulation of GM insects will be covered in
the following sections. It is important to realize that the determination of
jurisdiction is largely untested; 52 this paper will report on which agency
'"Id. at 23,302-03.
14 Id. at 23,303.
146 Id. at 23,302-03.
147 id.
148 Id. at 23,303.
149 The NIH through its Guidelines for Research Involving Recombinant DNA Molecules
places contractually binding regulations on researchers, however, if a researcher is doing
work not funded by the NIH, they are not bound to these guidelines. 51 Fed. Reg.
16,958, 16,959 (May 7, 1986).
o5 0 See PEW INITIATIVE ON FOOD & BIOTECHNOLOGY, supra note 26, at 49.
151 Coordinated Framework for Regulation of Biotechnology, 51 Fed. Reg. at 23,303-04.
152 To date only two field trials have been approved - GM pink bollworms in AZ and GM
mites in FL. See Trevor Thieme, Building a Better Pest, POPULAR SCIENCE, Oct. 2001, at
64, 67.
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could regulate a particular GM insect. Also, the type of GM insect and its
use will heavily dictate which agencies have primary jurisdiction over its
regulatory review. It is possible and likely, however, that more than one
agency and one set of regulations will apply to any one GM insect. The
fact that an agency has jurisdiction over one facet of GM insects does not
mean that it will have the capability to assess all relevant risks. This
section will be organized by agency; the order will be the FDA, the EPA,
and the USDA. Under each agency, different statutes and regulations will
be discussed.
B. Food and Drug Administration
The FDA is a vital federal agency which has the main task of
regulating food and drugs in the United States. This agency derives it
power from the Federal Food, Drug, and Cosmetic Act (hereinafter
"FFDCA").1 5 3  Although the Coordinated Framework concluded that
biotechnology products should be regulated, and not the process used to
create the products, most agencies differentiate biotech products from non-
biotech products based on the process and regulate based on a product's
GM status. The FDA, however, is the agency that has stayed closest to the
ideal of regulating the product and not the process.' 54 FDA's evaluation
of all drugs (GM insect or not) is based on whether each is "safe and
effective," a determination made after several rounds of testing.15 5 Prior
to an FDA finding of "safe and effective," several steps must occur. First,
the FDA must assert jurisdiction over the product. 156 Then, if jurisdiction
is proper, the producer must prove their product is "safe and effective" by
going through several regulatory steps. 1
'3 See 21 U.S.C. §§ 310-399 (2006).
154 See CTR. FOR VETERINARY MED., FOOD & DRUG ADMIN., GUIDANCE FOR INDUSTRY:
REGULATION OF GENETICALLY ENGINEERED ANIMALS CONTAINING HERITABLE
RECOMBINANT DNA CONSTRUCTS 4 (2009), available at
http://www.fda.gov/downloads/AnimalVeterinary/GuidanceComplianceEnforcement/Gui
danceforlndustry/UCM1 13903.pdf (stating that the FDA's policy is to regulate the article
produced (quoting 21 U.S.C. § 321(g)(1))).
15' 21 U.S.C. § 321(v)(1)-(2).
156 See id. subsec. (g)(1).




Although the FDA has yet to assert jurisdiction over a GM insect
release, the FDA has the potential to assert jurisdiction under the two-
pronged definition of a "drug." 5 8 This conclusion comes from a broad
reading of the definition of regulated articles.15 9 In 21 U.S.C. § 321
(g)(1), Congress defined the first prong of the FDA's regulatory
jurisdiction over a "drug" as a product "intended to affect the structure or
any function of the body of man or other animals . . . . "160 Genetic
modifications could be seen as affecting "the structure or any function" of
the transgenic insect because the alterations could affect the insidious
function of disease transmission. Also, production of a new protein would
alter the structure of the native species in that a new structure would be
present. Thus, broadly interpreted, any genetic modification would fall
under the FDA's purview if the intent is to alter the structure or any
function of the insect. In fact, in a non-binding guidance statement
provided by the FDA's Center for Veterinary Medicine (hereinafter
"CVM"), the CVM claimed jurisdiction over GM insects based solely on
the "structure or any function" provision.'61
Additionally, techniques using paratransgenesis would also likely fall
under this "structure or any function" definition of a drug. The genetic
modification of insect symbionts which would prevent the transmission of
diseases would, in a very broad sense, alter the function of the disease
vector. Thus, the FDA would also likely have regulatory authority over
insects altered via paratransgenesis.
The FDA must also satisfy the second part of the "drug" definition to
be able to assert jurisdiction. The second prong of the definition of "drug"
reads "articles intended for use in the diagnosis, cure, mitigation,
158 See 21 U.S.C. § 321(g)(1).
159 These broad readings are necessary because the FFDCA was originally drafted in
1906 at a time when none of these biotechnology innovations were remotely
contemplated.
'0 21 U.S.C. § 321(g)(1)(C).
161 CTR. FOR VETERINARY MED., FOOD & DRUG ADMIN., supra note 154, at 5.
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treatment, or prevention of disease in man or other animals."' 62  GM
insects that have been designed to either eliminate disease vectors, through
the SIT, or replace populations of competent vectors with those that are
refractory to carrying diseases may fall under this category. Insect
symbionts altered through paratransgenesis would likely be seen as
preventing disease; this would be another avenue for the FDA to assert
regulatory jurisdiction over those organisms. Also, GM insects, designed
for the above purposes are created to "prevent disease in man."
Additionally, if an insect was genetically modified to deliver a compound
to a human upon feeding (perhaps a vaccine), the GM insect could be
viewed as a drug delivery system. Thus, the FDA will likely be able to
satisfy both prongs of the jurisdictional requirements, giving it the ability
to regulate GM insects.
After a likely finding that GM insects are animal drugs, the FDA must
make further findings before regulatory action can be taken. The CVM of
the FDA has taken the position that GM animals (insects are animals) are
to be regulated like "new animal drugs."' 63 Under the FFDCA, "new
animal drugs" are to be "deemed unsafe" unless: (1) there is an approved
new animal drug application (hereinafter "NADA"); or (2) the drug is for
investigational uses and it conforms to the requirements of an
Investigational New Animal Drug (hereinafter "INAD"); or (3) the drug is
in compliance with other exceptions set forth in 21 U.S.C. § 360b(a)(4) or
(5).164 In effect, for a field trial of GM insects, if the FDA asserts
jurisdiction, a researcher would have to go through the regulatory phase
described below.
When applying for FDA approval, it is important that developers of
GM insects have refined their chosen lineage of insect. When directly
modifying an insect's genome via transposon or virus, these genetic
constructs can insert almost anywhere in the insect's DNA, meaning that
one hatching of insect offspring can have many different insertions. The
FDA has stated that each insertion requires its own approval.165 Thus, a
162 21 U.S.C. § 321(g)(1)(B).
161 CTR. FOR VETERINARY MED., FOOD & DRUG ADMIN., supra note 154, at 5.
16 Id. GM insects do not qualify for (3) as mandated by statute. 21 U.S.C. §
360ccc(a)(3)(A).
161 CTR. FOR VETERINARY MED., FOOD & DRUG ADMIN., supra note 154, at 5.
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manufacturer of GM insects has great incentive to select one lineage of
modified insects and seek approval for those after refinement.
In conclusion, it is likely that a broad reading of the FFDCA could be
construed to confer the FDA with regulatory authority over GM insects.
The next step in the process would be the actual regulatory steps imposed
by the FDA on GM insect producers.
2. FDA's Regulatory Process
If the FDA asserts jurisdiction over GM insects (which it likely will),
producers will face regulatory steps, which must be completed if they wish
to have their insects no longer "deemed unsafe." The FDA has stated that
there are certain circumstances where it will not assert jurisdiction,
however, the agency does reserve the right to do so if it sees fit. The two
circumstances where the FDA will not require an INAD and NADA
approval are: (1) GM insects not intended for food uses that other agencies
(such as USDA) will regulate; and (2) GM insects not intended for food
uses in a controlled environment, such as an approved laboratory.166 In
light of the recent push toward collaborative science, however, shipping of
GM insects for experiments at different facilities may be necessary. This
development will likely trigger the requirement for an INAD.
INAD regulations cover testing of GM animals and clinical
investigations associated with those animals.167  INAD regulations
generally require diligent record keeping, labeling of any shipping
containers, records regarding animal disposition, and whether or not the
animals or animal-derived products will enter the food supply.' 68 In the
case of GM insects under experimental investigation, it is likely that the
only requirements associated with an INAD would be for labeling of
shipments and record-keeping, as the GM insects are not likely to enter the
food supply at this early stage. Thus, prior to any interstate shipping of
GM insects, investigators will have to file an application with the FDA for
an INAD and meet the labeling and record-keeping requirements of 21
92
'6 Id. at 6.
167 See id. at 8.
161See 21 C.F.R. § 511.1 (2009).
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C.F.R. § 511.1(b). The FDA has urged the biotechnology industry to file
INAD notices as early as possible in the development process; however, it
is not required to do so until GM insects enter interstate shipping routes.169
A GM insect producer's INAD application will be reviewed for
compliance with FDA regulations, and because the approval of an INAD
is a "federal action," the procedural requirements of the National
Environmental Policy Act (hereinafter "NEPA") must be met as well.170
The NEPA requirements are intended to address any potential
environmental considerations associated with a "federal action," such as
regulatory approval.171 GM insect producers will have to file an
environmental assessment of their products' 72 or claim a categorical
exemption 73 if they can prove that extraordinary circumstances will not
exist, although NEPA considerations must still be noted in every "federal
action," regardless of the finding.174 Producers of GM insects, in their
INAD applications, will have to explain any significant potential adverse
impacts on the environment and describe containment methods designed
to prevent those impacts.175 Although environmental considerations are
highly relevant and important, NEPA considerations are only procedural;
the FDA is under no obligation to use those assessments in its decision.176
INAD applications will be important for GM insect developers in the
early stages; however, the actual NADA is the crucial hurdle to mass
release of GM insects. Approval of a new animal drug is based on
whether the drug's producer demonstrates the drug's safety and
efficacy.177 A NADA is a long and complex document with requirements
defined in 21 C.F.R. § 514.1; the technicalities of which are too detailed
for this paper. The most important inclusions in the NADA are: (1) how
the GM insect was created (including its full genotypic characterization);
169 CTR. FOR VETERINARY MED., FOOD & DRUG ADMIN., supra note 154, at 8.170Id. at 11.
171 Id.
17221 C.F.R. §§ 25.15, 511.1(b)(10).
'" Id. § 25.33(e).
174 Id. § 25.21.
1 See CTR. FOR VETERINARY MED., FOOD & DRUG ADMIN., supra note 154, at 11.
176 See id.
7 21 U.S.C. § 360b(a)(1) (2006).
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(2) providing samples of the GM insect; (3) evidence establishing safety
and efficacy; and (4) meeting NEPA requirements by filing either an
environmental assessment or claiming one of the categorical
exemptions. 178
One of the most powerful criticisms of the FDA asserting jurisdiction
for the regulation of GM insects stems from the complex nature of the
NADA application process. The FDA lacks the expertise to regulate the
environmental risks which will likely be a major issue for the release of
the GM insects. The FDA is geared toward the regulation of foods and
traditional "drugs," and, therefore, is not prepared to understand the
intricacies associated with the release of a GM insect and how it could
lead to severe environmental impacts. The "safe and effective" standard
will have little use when it comes to assessing impacts on ecosystems.
Another complaint regarding the FDA's regulatory process is its lack
of transparency. 1 The NADA process is confidential and the FDA is not
allowed to notify the public of a pending application.' 8 0 After approval of
an NADA, the FDA would release a summary of the data it used for
making its decision. In its recent guidance statement, the CVM of the
FDA stated that it wished to increase transparency in this process.182 To
accomplish this goal, the CVM stated that it would "hold public advisory
committee meetings prior to approving any [GM] animal."' 8 3 Although
this process has not been applied yet, this may assuage some of the
concerns associated with FDA approval of GM insects.
In conclusion, the FDA likely has the regulatory authority over any
GM insect set to be released. Producers of GM insects will probably have
to comply with the INAD application process during the developmental
phase and the NADA process prior to mass-release.
C. Environmental Protection Agency
'
7 8 See 21 C.F.R. § 511.1.
17 See PEW INITIATIVE ON FOOD & BIOTECHNOLOGY, supra note 26, at 69.
180 id.
SId.
182 CTR. FOR VETERINARY MED., FOOD & DRUG ADMIN., supra note 154, at 12.
13id.
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The EPA is the second of the three agencies to have regulatory power
of biotechnology products, per the Coordinated Framework. Charged with
regulating products, the EPA ensures that each product is safe for the
environment and for human use.184
Similar to the FDA, the EPA has yet to assert regulatory authority over
GM insects. The following sections will investigate how EPA could assert
regulatory jurisdiction over GM insects and the process that would follow.
1. Regulatory Jurisdiction
The EPA has two statutory avenues for the regulation of GM insects:
(1) the Federal Insecticide, Fungicide, and Rodenticide Act' 8 5 (hereinafter
"FIFRA"); and (2) the Toxic Substances Control Act' 86 (hereinafter
"TSCA"). If the FDA exerts its authority under the FFDCA, effectively
deciding that GM insects are either human or animal drugs; the EPA
cannot apply either FIFRA or TSCA.18 7
a. FIFRA
FIFRA gives the EPA broad regulatory discretion over "pesticides."
Congress has defined "pesticide" as "any substance or mixture of
substances intended for preventing, destroying, repelling, or mitigating
any pest."' 8 8 GM insects designed to eliminate or mitigate the impact of
agricultural pests, such as the GM screwworm and GM Mediterranean
fruit fly,89 would fit this definition of a pesticide because of its impacts
on those pests. Thus, although once again broadly construed to confer
regulatory authority, the EPA could assert regulatory jurisdiction over GM
insects based on FIFRA.
'" See U.S. EPA, About EPA, http://www.epa.gov/epahome/aboutepa.htm (last visited
Jan. 9, 2010).
1ss 7 U.S.C. §§ 136-136y (2006).
"6 15 U.S.C. §§ 2601-2695d (2006).
187 U.S.C. § 136(u); 15 U.S.C. § 2606.
1 7 U.S.C. § 136(u).




TSCA is a broad statute, under which the EPA controls non-drug or
non-pesticide compounds.190 Thus, if the FDA under FFDCA regulated
GM insects as a "drug" or if the EPA regulated GM insects as a
"pesticide," this statute would not apply.191 In light of these other two
more specific avenues for regulation, it is unlikely that the EPA would
assert jurisdiction under TSCA, however, it is still possible. The EPA
could use TSCA to gain regulatory authority over GM insects by defining
GM insects as a "chemical substance." Congress has defined a "chemical
substance" as "any or anic or inorganic substance of a particular
molecular identity . . . ." 92 This is a very broad-sweeping definition and
could include any substance as long as it has a "particular molecular
identity," which GM insects would possess because of their extensive
genotypic characterization. Thus, GM insects would probably fall under
this definition.
Additionally, EPA has used TSCA to promulgate regulations
governing GM microorganisms. The EPA has regulations which govern
"intergenic microorganisms."' 9 3 The agency defines these as including "a
microorganism which contains a mobile genetic element which was first
identified in a microorganism in a genus different from the recipient
microorganism." 94 Any insects altered through paratransgenesis would
be covered by this definition because of the alterations to bacterial flora in
their gut, but only if the gene has been transferred from one genus of
bacteria to another. Thus, any directly genome modified or paratransgenic
insect could be covered by TSCA.
One potential issue with TSCA jurisdiction related to
paratransgenic insects is that its review is limited to those GM
190 See Toxic Substances Control Act, 15 U.S.C. §§ 2601-2695d.
'9' See id. § 2602(2)(B)(ii), (vi).
192 Id. subsec. (2)(A).
193 40 C.F.R. § 725.3 (2009).
194 id
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microorganisms "with a commercial purpose."' 95 Many of the current
efforts are funded through the NIH, the Gates Foundation, or other entities
in a non-commercial setting. In those cases, TSCA could not be used to
confer regulatory jurisdiction on the EPA.
Overall, the EPA, through a broad reading of either FIFRA or
TSCA could assert regulatory jurisdiction over GM insects.
2. EPA's Regulatory Process
The manner in which the EPA would regulate GM insects would vary
depending on which statute the agency decided to utilize to obtain
jurisdiction. This section will analyze the regulatory steps for each statute.
a. FIFRA
Prior to the commercial release of any pesticide, it must be registered
with the EPA. 16 This would impose upon producers of GM insects the
requirement to gain registration status with the EPA prior to introduction
of GM insects into the environment.197 Registration entails a balancing of
the risks and benefits associated with any use of the pesticide. 98  To
obtain approval, the pesticide must "function without unreasonable
adverse effects on the environment . . . ."199 Congress had defined
"unreasonable adverse effects on the environment" as: "(1) any
unreasonable risk to man or the environment, taking into account the
economic, social, and environmental costs and benefits of the use of any
pesticide, or (2) a human dietary risk from residues that result from a use
of a pesticide in or on any food .... " 20 0 These standards would have to
be met with experimental data provided by producers of GM insects to
prove that the potential risks described in earlier sections of this essay do
not outweigh the potential benefits.
19 Id § 725.8(a)
196 7 U.S.C. § 136a (2006).
197 See id.
198 See id. § 136a(c)(5).




Additionally, to gather any data required to apply for a pesticide
permit, GM insect producers would likely need an "experimental use
permit."20 1 This permit would allow for the controlled use of GM insects
in confined quarters to gather data for the review process. 202
Overall, under FIFRA, the EPA would have to balance the risks to the
environment and to human health with the great potential benefits
associated with GM insects before the agency would grant approval.
b. TSCA
TSCA-based regulation requires that a party manufacturing a
"chemical substance" must submit a pre-manufacture notification to the
EPA at least ninety days prior to beginning manufacture. 203  This
submission is not required if the "chemical substance" is on the EPA's
TSCA Chemical Substances Inventory,204 a listing of approximately
83,000205 chemical substances. During this ninety day period, the EPA
will review all materials submitted with the pre-manufacture notice
including environmental and health effects, intended use, and intended
commercial distribution, among others. 206  Similar to regulation under
FIFRA, if not enough information is known, a balancing of risks against
benefits will ensue. 7
TSCA regulation can be tricky for GM insects. Depending on the
protein expressed, TSCA regulation may or may not be complicated. If
the genetic modification results in expression of a protein that is already
present on the EPA's Toxic Substances list, the regulatory steps may be
simple because the pre-manufacture notification steps will not be
necessary. If the protein is not on the EPA's list, however, the steps
201 See id. § 136c.
202 See id. subsec. (a).
203 15 U.S.C. § 2604(a) (2006).
204 Neil A. Belson, US Regulation ofAgricultural Biotechnology: An Overview, 3 J.
AGROBIOTECHNOLOGY MGMT. & ECON. 268, 273 (2000).205 U.S. EPA, What is the TSCA Chemical Substance Inventory?,
http://www.epa.gov/oppt/newchems/pubs/invntory.htm (last visited Nov. 13, 2009).
206 15 U.S.C. § 2604(a).
207 See id. § 2605.
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associated with the "pre-manufacture notice" may be more onerous.
The EPA has given some indication that regardless of whether the
FDA determines that a GM insect is a "drug," the EPA believes it can still
regulate under TSCA. The EPA believes that the "drug" component of the
GM insect is the genetic modification; however, the entire GM insect
(including all components - natural or GM) is a "chemical substance"
208
under TSCA. This adds to the confusion associated with the regulation
of GM insects.
One important positive that would come from EPA regulation is the
transparency associated with regulation either under FIFRA or TSCA.
Applications to the EPA, under either of these statutes, require a public
notice period with a mandatory publication in the Federal Register.209
One exception is confidential business information. Per TSCA, a
manufacturer can designate disclosure to the EPA under TSCA as
"confidential," which restricts its release in the Federal Register.210
Potentially, a GM insect producer could attempt to deem their product
"confidential" and try to restrict its publication in the Federal Register.
However, some public comment and discourse on these topics is possible.
This may help the public perception of the regulation of GM insects.
In conclusion, the EPA likely has two different routes to regulate GM
insects, FIFRA and TSCA. Regulation under these statues is largely a
matter of balancing the risks against the benefits associated with GM
insects. Once again, it is entirely possible for the EPA in conjunction with
other agencies to assert control, making the regulatory process difficult to
apply.
D. U.S. Department ofAgriculture
The USDA has broad statutory authority to regulate and promote U.S.
agriculture and to protect it from potential threats such as animal illnesses
and plant pests. In terms of biotechnology and protecting U.S. agriculture
from pests, the USDA largely functions through the Animal and Plant
208 See COUNCIL ON ENVTL. QUALITY, OFFICE OF SCI. & TECH. POLICY, CASE STUDIES OF
ENVIRONMENTAL REGULATION FOR BIOTECHNOLOGY (2001).
209 7 U.S.C. § 136a-l(d) (2006); 15 U.S.C § 2604(d).
210 15 U.S.C. § 2613(a).
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Health Inspection Service (hereinafter "APHIS").2 1' APHIS regulates all
items that could be introduced which could potentially harm U.S.
agriculture.212 The USDA, functioning through APHIS, could assert
jurisdiction over GM insects using two broad statutes, the Plant Protection
Act213 and the Animal Health Protection,214 and one narrow statute, the
Honeybee Act.215
1. USDA's Jurisdiction
a. Plant Protection Act
The Plant Protection Act (hereinafter "PPA"), enacted in 2000
(replacing the Federal Plant Pest Act), was originally intended to prevent
the introduction and movement of traditional "plant pests," but has been
broadly interpreted to include products of biotechnology.2 16  The PPA
gives APHIS regulatory control over any articles that could be considered
"plant pests."217 Congress has defined "plant pests" as "any living stage
of any of the following that can directly or indirectly injure, cause damage
to, or cause disease in any plant or plant product . . . [including a]
nonhuman animal."218 GM insects that are created to limit agricultural
pests that have the potential to destroy crops, such as a GM Mediterranean
fruit fly, could fit under this definition of a "plant pest" because GM fruit
flies are "plant pests" with a genetic modification. Even though the GM
fruit fly will mate and produce non-viable offspring, the release of the GM
fruit fly would effectively be the release of an organism that could damage
hundreds of types of plants. Thus, any GM insect created to alleviate the
effects of a "plant pest" would likely fall under this definition.
211 United States Regulatory Unified Biotechnology Website, Roles of U.S. Agencies,
http://usbiotechreg.nbii.gov/roles.asp (last visited Dec. 19, 2009).
212 See U.S. Department of Agriculture, Animal and Plant Health Inspection Service,
http://www.aphis.usda.gov/ (last visited Jan. 9, 2010).
213 7 U.S.C. §§ 7701-7786.
2 14 Id. §§ 8301-8322.
215 Id. §§ 281-286.
216 See id. § 7701; 7 C.F.R. § 340.0 (2009).
217 7 U.S.C. § 7711.
2181d. § 7702(14)(B).
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The PPA also gives APHIS regulatory authority over "biological
control organisms." 9 APHIS may regulate use of "biological control
organisms," much like it may regulate "plant pests." Congress has defined
"biological control organisms" as "any enemy, antagonist, or competitor
used to control a plant pest . . . .,,220 This definition is a more accurate
description because all GM insects designed to eliminate or mitigate a
"plant pest" are an enemy of that "plant pest." A GM insect would be
created to control a plant pest, like the Mediterranean fruit fly, and thus
USDA through APHIS would have regulatory jurisdiction over GM
insects under either the "plant pest" or "biological control organism"
provisions of the PPA. Additionally, paratransgenic insects may also fit
under the definition of a "biological control organism." The
microorganisms, genetically engineered to function as a disease control
agent, would be designed to work as an "enemy" or "antagonist" of pests;
thus these microorganisms would also likely be covered. Also, to date,
APHIS, under the PPA, is the only regulatory body to assert and regulate a
field trial of a GM insect, the GM pink bollworm.
One final note is that the state of regulations under the PPA may be in
flux. On October 9, 2008, APHIS published changes to its regulatory
scheme in the Federal Register. 222 PPA requested comments and later had
to extend the comment period.223 Public meetings to discuss regulatory
changes were scheduled for April 2009, although no further actions have
been taken.224
219 See id. § 7712.220 1d. § 7702(2).
221 PEW INITIATIVE ON FOOD & BIOTECHNOLOGY, supra note 26, at 56-57.
222 Importation, Interstate Movement, and Release into the Environment of Certain
Genetically Engineered Organisms, 73 Fed. Reg. 60,008 (proposed Oct. 9, 2008) (to be
codified at 7 C.F.R. pt. 340).
223 Introduction of Organisms and Products Altered or Produced Through Genetic
Engineering, 74 Fed. Reg. 10,517 (proposed Mar. 11, 2009) (to be codified at 7 C.F.R. pt.
340).
224 Id., see ANIMAL & PLANT HEALTH INSPECTION SERV., U.S. DEP'T OF AGRIC., ISSUE






b. Animal Health Protection Act
The Animal Health Protection Act (hereinafter "AHPA")225 was
enacted in 2002 to aid in preventing, controlling, detecting, and
eradicating animal diseases and pests. Under AHPA, APHIS has the
broad authority to protect against animal diseases and pests, including
disease vectors, such as insects.227 Congress has defined "pests" as "any
of the following that can directly or indirectly injure, cause damage to, or
cause disease in livestock . .. [including a]n arthropod." 228 Similar to the
argument for plant pests, GM insects, created to limit diseases vectored by
insects, could still cause injury to animals; GM insects may still need to
feed on animals to survive. Now, it is possible that only male insects
would be released. Generally the male insect does not blood feed and thus
does not spread disease, meaning that if only males are released the GM
insects would be unable to injure livestock, either directly or indirectly.
This would be a consideration for designers of GM insects. Thus,
depending on the potential of the GM insect to injure animals, no matter
how beneficial it may be in wiping out disease vectors, it may be regulated
under AHPA.
c. Honeybee Act
The Honeybee Act was originally enacted to give APHIS the authority
to regulate importation of honeybees to limit the impact of "Africanized"
bees. 29 Under this act, APHIS has the authority "to prohibit or restrict the
importation or entry of honeybees . . . into or through the United States ...
."230 Although limited to only one type of GM insect, this Act could
nonetheless apply. As described above, genetic modification of
honeybees is being considered, and under a broad reading of this statute,
GM honeybees would be covered. After all, GM honeybees are still
225 7 U.S.C. §§ 8301-8322 (2006).226 1d. § 8301(1).
227 See id. §§ 8301-8322.
2281d. § 8302(13)(G).
229 PEW INITIATIVE FOR FOOD & BIOTECHNOLOGY, supra note 26, at 57.
230 7 U.S.C. § 281(a).
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honeybees with added genes.
In conclusion, the USDA, through APHIS, could easily assert
regulatory jurisdiction through a broad reading of the PPA, AHPA, or the
Honeybee Act.
2. USDA's Regulatory Process
One of the first steps in APHIS' regulatory process is consideration of
the NEPA procedural requirements.231 Similar to what was described in
the FDA section, APHIS must consider an environmental assessment to
determine if the release under the PPA, AHPA, or the Honeybee Act
would cause a major environmental concern. 232 If APHIS determines that
the release of a GM insect (only the GM insect applying for a permit)
would not pose a significant environmental threat, APHIS will issue a
233finding of no significant impact. If APHIS has concerns about the
environmental impact, the agency can order an environmental impact
statement to be prepared.234 Interestingly, for the release of the GM
bollworm in Arizona, APHIS issued a finding of no significant impact. 235
Although not required, APHIS proceeded to carry out an environmental
impact statement, in spite of the finding of no significant impact.2 36 The
environmental impact statement illustrated there were no expected
environmental concerns associated with the field testing of the GM pink
bollworms.237
Currently, APHIS has developed rules that could be, and have been,
used for the release of GM insects under the PPA. Prior to the release of a
GM organism, APHIS must be notified and may require a permit to be
231 See 7 C.F.R. § 372.1 (2009).
232 PEW INITIATIVE FOR FOOD & BIOTECHNOLOGY, supra note 26, at 60.
233 d
234 d
235 Availability of Environmental Assessment and Finding of No Significant Impact for
Confined Field Test of Genetically Engineered Pink Bollworm, 67 Fed. Reg. 1434 (Jan.
11, 2002).
236 Environmental Impact Statement; Genetically Engineered Pink Bollworm, 67 Fed.




issued.238 APHIS has the power to place certain articles under an
exemption for a permit, requiring only notice, but not a permit. 239 This,
however, may change in the proposed revisions to the USDA
regulations 240 discussed above. There are several requirements that must
be met to fit under the exemptions list, one of which is that the article must
be a plant, 24 1 thus GM insects will not fit under this exemption list.
APHIS' permit process is similar to other agencies' regulatory
processes. GM insect producers would be required to provide copious
amounts of information so that the agency can perform a risk assessment
as to whether the organism can be controlled. Similar to the EPA's
requirements, APHIS requires information regarding the GM insect's
genotype, ecological considerations, biology, mating fitness, a risk
assessment, and control mechanisms, among other information that can be
used in a risk balancing manner.243
A permit will not be issued or will be cancelled once issued, if the
safeguards associated with containing the "plant pest" are not adequate or
if the risks of dissemination outweigh the benefits.244 This point can be
important for later commercial development of GM insects. The
containment procedures for field testing are understandable; APHIS does
not wish to allow GM insects to spread until it knows that the insects will
properly function. However, GM insects' entire purpose will be
dissemination and population eradication or replacement. If defined as a
"plant pest," conflict could arise in allowing full release. To date, no GM
insects have been fully released (SIT insects aside), thus, the regulations,
and how each will be adapted to that process, have yet to be tested.
APHIS, although likely possessing jurisdiction under AHPA and the
Honeybee Act, has not yet promulgated regulations to address how GM
23 7 C.F.R. § 340.4 (2009).239 Id. § 340.3.
240 See Performance Specification and Quality Assurance Requirements for Continuous
Parameter Monitoring Systems, 73 Fed. Reg. 59,956 (Oct. 9, 2008).
241 7 C.F.R. § 340.3(b)(1).
242 See id. § 340.4; Animal and Plant Health Inspection Service, Transgenic Insect Permit
Guidance, http://www.aphis.usda.gov/biotechnology/arthropods.shtml (last visited Nov.
13, 2009).243 Animal and Plant Health Inspection Service, supra note 242.244 7 C.F.R. § 330.204.
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insects could be regulated under these statutes.
Finally, the transparency of APHIS' process is similar to the EPA.
APHIS will provide (and has provided in the case of the GM pink
bollworms) notice of regulatory actions in the Federal Register, allowing
time for public comment and hearings. This will be helpful in assuaging
the public's concerns with the regulatory process.
In conclusion, the USDA, through APHIS, has regulatory jurisdiction
over GM insects. Its regulatory process has already experienced the
granting of a permit for GM pink bollworms for limited, contained release
in Arizona. Although APHIS has only experienced minor testing of its
process, it appears to have been successful. With the proposed rule
changes that were published in the Federal Register last year, this process
will likely change, with unknown consequences.
E. International Regulation
The final destination of some GM insects developed in the United
States will be abroad. As detailed in earlier sections, one of the significant
motivations for the design and release of GM insects is to limit the
transmission of tropical diseases. These diseases are endemic abroad, thus
international regulations will be highly relevant for GM insect producers.
The current state of international regulation is in flux. In 2002, the
Food and Agricultural Organization of the United Nations, in conjunction
with the International Atomic Energy Association held a meeting in
Rome to discuss GM insects, including their regulation. 245 One of the
conclusions from the conference was that "[c]urrent national regulatory
processes, including the availability of suitable risk analysis protocols,
may be insufficient to address any eventual release of transgenic
arthropods." 246 This illustrates how difficult it will be for developers of
GM insects to obtain regulatory approval, if even available in target
countries.
245 FAO/IAEA AGRICULTURE & BIOTECHNOLOGY LAB., INT'L ATOMIC ENERGY AGENCY,
STATUS AND RISK ASSESSMENT OF THE USE OF TRANSGENIC ARTHROPODS IN PLANT





Another concern is the stability of target countries. It is entirely
possible that a regulatory regime, similar to what is available in the United
States, will not be present in a target country because of the lack of
stability of governments in some of these developing nations. These
concerns highlight just some of the problems that producers of GM insects
will face when seeking regulatory approval abroad.
In spite of this uncertainty, one regulatory mechanism that will likely
apply is the Cartagena Protocol on Biosafety (hereinafter "Protocol").
This Protocol was adopted as a part of the Convention on Biological
Diversity to apply to "transboundary movement, transit, handling and use
of all living modified organisms that may have adverse effects on the
conservation and sustainable use of biological diversity . . . . The
Protocol defines "living modified organism" as "any living organism that
possesses a novel combination of genetic material obtained through the
use of modern biotechnology." 2 48 Thus, a GM insect would likely fall
under the Protocol, especially because of its ability to move not only
across ecosystems, but also across transnational boundaries. The Protocol
does, however, exempt living modified organisms which can serve as
pharmaceuticals.249 Thus, if a GM insect was created to transmit a
vaccine-like dose of an antigen for human use, the Protocol may not apply.
Although GM insects would likely fall under the Protocol, this
document serves only as a notification system among countries that are
signatories to the Protocol. The Protocol requires that advanced notice be
given to the country where the living modified organisms are to be
shipped. 250 This notice only applies to organisms that will be released into
the environment and includes detailed information about the GM
organism.251 Also, to date, the United States is not a signatory to the
247 Cartagena Protocol on Biosafety to the Convention on Biological Diversity art. 4, Jan.
29, 2000, 2226 U.N.T.S. 257, available at
http://untreaty.un.org/unts/144078_158780/6/5/13663.pdf.
248 Id. art. 3(g).
249 Id. art. 5.250 Id art. 8.
251 Id. art. 7, annex I.
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Protocol, and is not subject to its requirements. 252 Currently, the Protocol
functions only as an advanced warning system for countries into which
GM insects would be shipped; there is not a liability or redress system
associated with it.
Overall, prior to implementation of a strategy using GM insects,
much more work will have to be done to implement a regulatory
framework that is capable of dealing with their release. Aside from a
purely domestic regulatory framework, which may or may not be present,
an international set of regulations would be beneficial to all involved.
CONCLUSION
In conclusion, GM insects will likely be a necessary part of our future.
Many needs for GM insects are present. Those needs include mitigating
public health disasters associated with tropical disease, assuaging the
burdens of crop and livestock pests, and the endless potential that comes
with altering insects to produce pharmaceuticals. Although, there are
different views on the risks and rewards associated with GM insects, the
regulatory process helps to balance the two. The Coordinated Framework
has created a system wherein the FDA, the EPA, and the USDA will be
(and have been) able to regulate GM insects. There is, however, a lack of
adequate clarity on which agency will regulate GM insects and whether
the insect's intended use or some other measure will govern which agency
regulates which GM insect. Finally, there is a dearth of information
regarding international regulation. Producers of GM insects will need to
know how their products will be regulated on foreign shores because so
many of the motivations for GM insects are abroad. Overall, GM insects
will become a necessary part of our future.
252 See Convention on Biological Diversity, List of Parties,
http://www.cbd.int/biosafety/parties/list.shtml (last visited Jan. 9, 2010) (listing countries
with their date of ratification and further listing the United States without a date of
ratification).
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